Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Lucie Hijmering-Kappelle"'
1
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
Autor: Danique Giesen, E. L. van der Veen, J.B.A.G. Haanen, A. J. van der Wekken, Derk Jan A. de Groot, Lucie Hijmering-Kappelle, Mathilde Jalving, P P van de Donk, H.J.M. Groen, M. N. Lub-de Hooge, Adrienne H. Brouwers, E.G.E. de Vries, Wim Timens, Iris C. Kok, B. van der Hiel, W Uyterlinde, Sjoerd G. Elias, G.A.P. (Geke) Hospers, J A Hooiveld, Thijo J N Hiltermann
Publikováno v: Annals of Oncology, 33(1), 80-88. Oxford University Press
Annals of Oncology
Background: Programmed cell death protein 1 (PD-1) antibody treatment is standard of care for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients will benefit is currently not possible. Tumor uptake and biodistributi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781376a45d3e69e26c46f1276c3106dc
https://doi.org/10.1016/j.annonc.2021.10.213
Zobrazit plný text záznamu
2
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles
Autor: Birgitta I. Hiddinga, Arja ter Elst, T. Jeroen N. Hiltermann, Matthew Groves, Bart Koopman, Harry J.M. Groen, Anthonie J. van der Wekken, Ed Schuuring, Lucie Hijmering-Kappelle, Wim Timens, Anke van den Berg, Juliana F Vilacha, Léon C van Kempen, Jos A. Stigt
Publikováno v: JCO Precision Oncology, 4, 393-410. AMER SOC CLINICAL ONCOLOGY
PURPOSE Molecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc46748b206272d2dd83a309a0dd0562
https://doi.org/10.1200/PO.20.00008
Zobrazit plný text záznamu
3
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
Autor: Wilfred F. A. den Dunnen, Bart Koopman, Juliana F Vilacha, T. Jeroen N. Hiltermann, Harry J.M. Groen, Wim Timens, Joost Kluiver, Lucie Hijmering-Kappelle, Matthew Groves, Birgitta I. Hiddinga, Ed Schuuring, Anthonie J. van der Wekken, Anke van den Berg, Michel van Kruchten, Léon C van Kempen, Arja ter Elst
Publikováno v: Clinical lung cancer, 23(2), e104-e115. CIG MEDIA GROUP, LP
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with Anaplastic Lymphoma Kinase (ALK) gene fusions respond well to ALK inhibitors but commonly develop on-target resistance mutations. The objective of this study is to collect clinical eviden
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9316808711f0c984863e62b3decfe59
https://pubmed.ncbi.nlm.nih.gov/34325996
Zobrazit plný text záznamu
5
Abstract 399: ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy
Autor: Lucie Hijmering-Kappelle, Birgitta. L. Hiddinga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Anthonie J. van der Wekken, Maria L. Aguirre Azpurua, Wim Timens
Publikováno v: Cancer Research. 79:399-399
Introduction: Immunotherapy is a breakthrough in non-small cell lung cancer (NSCLC), showing long lasting responses in metastasized disease. However, only a limited number of patients responds to treatment. Selection of patients by known biomarkers (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f212b33998fe24d51cfcf5ceb610bef1
https://doi.org/10.1158/1538-7445.am2019-399
Zobrazit plný text záznamu
6
Abstract 4067: PD-L1 expression, CD8 cells and MHC-class-1 Beta-2-microglobulin expression in advanced non-small lung cancer
Autor: Anthonie J. van der Wekken, Lucie Hijmering-Kappelle, Jeroen Hiltermann, Harry J.M. Groen, Nils A. 't Hart, Wim Timens, Birgitta I. Hiddinga
Publikováno v: Cancer Research. 79:4067-4067
Introduction: PD-L1 expression has been approved as predictive biomarker for immune checkpoint inhibitors (ICI) in non-small cell lung carcinoma (NSCLC). In case of lack of PD-L1 expression in tumor biopsies, 8-10% of patients will respond to ICI. Ho
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0e441d3e7fe4b39da686cab93e619da
https://doi.org/10.1158/1538-7445.am2019-4067
Zobrazit plný text záznamu
8
Abstract 2718: Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations
Autor: Ed Schuuring, Thijo J N Hiltermann, Arja ter Elst, Matthew Groves, Harry J.M. Groen, Anke van den Berg, Anthonie J. van der Wekken, Wim Timens, Nils A. 't Hart, Lucie Hijmering-Kappelle
Publikováno v: Cancer Research. 77:2718-2718
Purpose: To evaluate treatment response following the Multidisciplinary Molecular Tumor Board (MTB) decisions which focused on EGFR exon 20 mutations in lung adenocarcinoma. Methods: Molecular studies were routinely performed using the Ion Torrent se
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3fa7974b3f670de99f5333145be8d98e
https://doi.org/10.1158/1538-7445.am2017-2718
Zobrazit plný text záznamu
9
Very early molecular marker of tumor response to PD-1 inhibition in plasma of patients with advanced non-small cell lung cancer (NSCLC)
Autor: Harry J.M. Groen, Ed Schuuring, Thijo J N Hiltermann, Anneke Miedema, Lucie Hijmering-Kappelle
Publikováno v: Journal of Clinical Oncology. 35:3030-3030
3030 Background: Nivolumab shows a durable tumor response in 20 % of advanced NSCLC patients. While a PD-L1 immunohistochemistry complementary diagnostic has been approved, there is a need to identify a predictive biomarker with greater diagnostic ac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2de7b3cbdb0125486b1e6e91320b4f07
https://doi.org/10.1200/jco.2017.35.15_suppl.3030
Zobrazit plný text záznamu
10
Markers of response to PD-1 inhibition
Autor: Thijo J N Hiltermann, Lucie Hijmering-Kappelle, Harry J.M. Groen
Publikováno v: Journal of Clinical Oncology. 35:e14505-e14505
e14505 Background: Nivolumab (Nivo) has a durable tumour response in 20 % of patients. While a PD-L1 IHC complementary diagnostic has been approved, there is a need to identify a predictive biomarker with greater diagnostic accuracy. Serum biomarkers
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e00deabb15b5245a5a11050a5e84c67c
https://doi.org/10.1200/jco.2017.35.15_suppl.e14505
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje